Neurotech International (ASX:NTI) said the 28-day good laboratory practice oral toxicology studies in rats and dogs evaluating its NTI164 drug candidate demonstrated excellent tolerability and no safety concerns, according to a Monday Australian bourse filing.
The animals received twice-daily oral dosing across low, mid, and high dose levels, followed by a 14-day recovery period.
It said that no test article-related adverse effects were observed across clinical observations, ophthalmic exams, neurological assessments, or clinical pathology.
The firm is focused on treating paediatric neurological disorders via the NTI164 broad-spectrum oral cannabinoid drug therapy candidate.
Its shares rose 9% on Monday's close.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。